Latest stories on CMPS
Compass Pathways: A Compelling Opportunity In A Large And Underserved Market
Seeking Alpha64 · neutralanalyst
Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026
StockTitan50 · neutralgeneral
B.Riley reiterates Buy on Compass Pathways stock, $22 target
Investing.com Analyst Ratings63 · neutralanalyst
After a long, strange trip, this CEO is close to taking a psilocybin pill to market
Business Insider74 · bullishproduct/pr
Compass Pathways: Built The FDA's Way, Valued At 0.57x Spravato's Sales
Seeking Alpha64 · neutralanalyst
Cathie Wood’s ARK Investment buys 284K shares of Compass Pathways today
The Fly63 · neutralgeneral
Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
Stocktwits News48 · neutralgeneral
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
StockTitan50 · neutralgeneral
Compass Pathways names Kelley Boucher as Chief People Officer
The Fly55 · neutralgeneral
Compass Pathways Appoints Kelley Boucher as Chief People Officer
StockTitan55 · neutralgeneral
COMPASS Pathways plc (CMPS) Presents at Deutsche Bank 2026 Healthcare Summit Transcript
Seeking Alpha56 · neutralgeneral
COMPASS Pathways plc (CMPS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha56 · neutralgeneral
Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026
StockTitan56 · neutralproduct/pr
Strata Mental Health Solutions awarded training grant by Compass Pathways
The Fly63 · neutralgeneral
Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training
PR Newswire63 · neutralproduct/pr
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training
StockTitan56 · neutralproduct/pr
Compass Pathways to Participate in Investor Conferences the Week of September 14th
StockTitan55 · neutralgeneral
Oppenheimer reiterates Compass Pathways stock rating on trial data
Investing.com Analyst Ratings56 · neutralanalyst
Jefferies reiterates Compass Pathways stock rating on TRD approval confidence
Investing.com Analyst Ratings56 · neutralanalyst
Compass Pathways stock shows durable results in depression trial
Investing.com Analyst Ratings67 · bullishproduct/pr
CMPS Stock Defies Market Selloff After Compass Pathways Psilocybin Trial Success Pointing To 2027 Launch
Stocktwits News73 · bullishproduct/pr